Loading...
•
Mar 31, 2020
Ultragenyx Q1 2020 Earnings Report
Ultragenyx reported strong financial results with total revenue of $36.3 million and maintained full year 2020 financial guidance.
Key Takeaways
Ultragenyx reported first quarter 2020 financial results, with total revenue of $36.3 million. The company maintains full year 2020 guidance based on COVID-19 impact to date. The FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track to be completed in the coming months.
Total revenue for the first quarter of 2020 was $36.3 million.
Crysvita revenue in Ultragenyx territories was $28.8 million.
The company maintains full year 2020 guidance.
FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track.
Revenue by Segment
Forward Guidance
The company currently maintains the guidance range for 2020 Crysvita revenue in the Ultragenyx territories to be between $125.0 million and $140.0 million, although it continues to monitor the COVID-19 pandemic situation. The company also expects a more than 20 percent reduction in net cash burn in 2020 compared to 2019 due to a combination of financial discipline in spending with flattening operating expense growth, combined with a significant anticipated growth in revenue.
Positive Outlook
- Crysvita revenue guidance maintained between $125.0 million and $140.0 million.
- Expects a more than 20% reduction in net cash burn in 2020 compared to 2019.
- Financial discipline in spending.
- Flattening operating expense growth.
- Significant anticipated growth in revenue.
Challenges Ahead
- Continues to monitor the COVID-19 pandemic situation.
- Potential delays in clinical trials due to COVID-19
- Uncertainties related to insurance coverage and reimbursement approval for the company’s products
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...